Adipose tissue lipoma |
Abdominal cavity |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
Abdominal cavity |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
Abdominal cavity |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
CNS - Brain |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
CNS - Brain |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
CNS - Brain |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
CNS - Brain |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
6.7 |
0 |
|
|
|
|
Summary
|
Adipose tissue lipoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Adrenal gland - Cortex adenoma |
Adrenal gland - Cortex |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0.8 |
|
|
|
|
Summary
|
Adrenal gland - Cortex adenoma |
Adrenal gland - Cortex |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
2.2 |
|
|
|
|
Summary
|
Adrenal gland - Cortex adenoma |
Adrenal gland - Cortex |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
2.2 |
|
|
|
|
Summary
|
Adrenal gland - Medulla pheochromocytoma |
Adrenal gland - Medulla |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Adrenal gland - Medulla pheochromocytoma |
Adrenal gland - Medulla |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 1.1 |
0 |
|
|
|
|
Summary
|
Adrenal gland - Medulla pheochromocytoma |
Adrenal gland - Medulla |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Adrenal gland - Medulla pheochromocytoma |
Adrenal gland - Medulla |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Adrenal gland - Medulla pheochromocytoma |
Adrenal gland - Medulla |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Adrenal gland - Medulla pheochromocytoma |
Adrenal gland - Medulla |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
6.7 |
|
|
|
|
Summary
|
Blood vessel hemangiosarcoma |
Blood vessel |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Blood vessel hemangiosarcoma |
Blood vessel |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0.6 |
|
|
|
|
Summary
|
Blood vessel hemangiosarcoma |
Blood vessel |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
1.5 |
|
|
|
|
Summary
|
Bone lesion - fibro-osseous |
Bone |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Bone lesion - fibro-osseous |
Bone |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
93.3 |
66.7 |
|
|
|
|
Summary
|
Bone lesion - fibro-osseous |
Bone |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Bone lesion - fibro-osseous |
Bone |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
100 |
46.7 |
|
|
|
|
Summary
|
Bone lesion - fibro-osseous |
Bone |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
6.7 |
0 |
|
|
|
|
Summary
|
Bone lesion - fibro-osseous |
Bone |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
66.7 |
33.3 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 0.6 |
0 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 - 0.8 |
0 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 - 6.7 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
13.3 |
33.3 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Bone osteosarcoma |
Bone |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
20 |
|
|
|
|
Summary
|
CNS - Brain glioma |
CNS - Brain |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
CNS - Brain glioma |
CNS - Brain |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
CNS - Brain glioma |
CNS - Brain |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
CNS - Brain glioma |
CNS - Brain |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
CNS - Brain glioma |
CNS - Brain |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
CNS - Brain glioma |
CNS - Brain |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
6.7 |
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Skin |
None (spontaneous) |
C57BL/6JIco
inbred
|
0.8 |
0 |
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Skin |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0.6 |
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Skin |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 |
0 |
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Uterus - Cervix |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
|
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Uterus - Cervix |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
0 |
|
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Uterus - Cervix |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Uterus - Cervix |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Uterus - Cervix |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Connective tissue - Fibroblast fibrosarcoma |
Uterus - Cervix |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
6.7 |
|
|
|
|
|
Summary
|
Forestomach tumor |
Forestomach |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
C57BL/6JIco
inbred
|
6.7 |
6.7 |
|
|
|
|
Summary
|
Forestomach tumor |
Forestomach |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 40 |
0 - 33.3 |
|
|
|
|
Summary
|
Gallbladder papilloma |
Gallbladder |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Gallbladder papilloma |
Gallbladder |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
26.7 |
0 |
|
|
|
|
Summary
|
Gallbladder papilloma |
Gallbladder |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
13.3 |
0 |
|
|
|
|
Summary
|
Intestine - Small Intestine adenocarcinoma |
Intestine - Small Intestine |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
6.7 |
|
|
|
|
Summary
|
Intestine - Small Intestine adenocarcinoma |
Intestine - Small Intestine |
Chemical/Drug
WY-14,643
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Intestine - Small Intestine adenocarcinoma |
Intestine - Small Intestine |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Intestine - Small Intestine adenocarcinoma |
Intestine - Small Intestine |
Chemical/Drug
WY-14,643
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Intestine - Small Intestine tumor |
Intestine - Small Intestine |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
observed - 1.7 |
|
|
|
|
Summary
|
Intestine - Small Intestine tumor |
Intestine - Small Intestine |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Intestine - Small Intestine tumor |
Intestine - Small Intestine |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
1.5 |
|
|
|
|
Summary
|
Intestine tumor |
Intestine |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
C57BL/6JIco
inbred
|
0 |
40 |
|
|
|
|
Summary
|
Intestine tumor |
Intestine |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 46.7 |
0 - 26.7 |
|
|
|
|
Summary
|
Kidney adenoma |
Kidney |
Chemical/Drug
phenacetin
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
observed |
|
|
|
|
|
Summary
|
Kidney hyperplasia |
Kidney |
Chemical/Drug
phenacetin
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Kidney hyperplasia |
Kidney |
Chemical/Drug
phenacetin
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
observed |
observed |
|
|
|
|
Summary
|
Kidney hyperplasia |
Kidney |
Chemical/Drug
phenacetin
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
observed |
observed |
|
|
|
|
Summary
|
Kidney transitional cell carcinoma |
Kidney |
Chemical/Drug
p-cresidine
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Kidney transitional cell carcinoma |
Kidney |
Chemical/Drug
p-cresidine
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 - 6.7 |
|
|
|
|
Summary
|
Kidney transitional cell carcinoma |
Kidney |
Chemical/Drug
p-cresidine
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
6.7 |
13.3 - 20 |
|
|
|
|
Summary
|
Kidney tumor |
Kidney |
Chemical/Drug
phenacetin
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Kidney tumor |
Kidney |
Chemical/Drug
phenacetin
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Kidney tumor |
Kidney |
Chemical/Drug
phenacetin
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
observed |
0 |
|
|
|
|
Summary
|
Leukocyte - Monocyte - Macrophage - Histiocyte histiocytic sarcoma |
Leukocyte - Monocyte - Macrophage - Histiocyte |
None (spontaneous) |
C57BL/6JIco
inbred
|
0.8 |
0 |
|
|
|
|
Summary
|
Leukocyte - Monocyte - Macrophage - Histiocyte histiocytic sarcoma |
Leukocyte - Monocyte - Macrophage - Histiocyte |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0.6 |
|
|
|
|
Summary
|
Leukocyte - Monocyte - Macrophage - Histiocyte histiocytic sarcoma |
Leukocyte - Monocyte - Macrophage - Histiocyte |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) leukemia - myelocytic |
Leukocyte - Myelocyte (Granulocyte) |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) leukemia - myelocytic |
Leukocyte - Myelocyte (Granulocyte) |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
6.7 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) leukemia - myelocytic |
Leukocyte - Myelocyte (Granulocyte) |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) leukemia - myelocytic |
Leukocyte - Myelocyte (Granulocyte) |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) leukemia - myelocytic |
Leukocyte - Myelocyte (Granulocyte) |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) leukemia - myelocytic |
Leukocyte - Myelocyte (Granulocyte) |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) sarcoma - myeloid |
Leukocyte - Myelocyte (Granulocyte) |
None (spontaneous) |
C57BL/6JIco
inbred
|
0.8 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) sarcoma - myeloid |
Leukocyte - Myelocyte (Granulocyte) |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte - Myelocyte (Granulocyte) sarcoma - myeloid |
Leukocyte - Myelocyte (Granulocyte) |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 - 2.5 |
0 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 1.1 |
0 - 0.6 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 - 2.3 |
0 - 13.3 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
C57BL/6JIco
inbred
|
13.3 |
0 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
26.7 - 66.7 |
13.3 - 33.3 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Chemical/Drug
Cyclosporin A
|
C57BL/6JIco
inbred
|
0 - 21.4 |
0 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Chemical/Drug
Cyclosporin A
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 28.6 |
0 - 30.8 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Chemical/Drug
Cyclosporin A
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
40 - 50 |
13.3 - 72.7 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
0 |
6.7 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 - 6.7 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
13.3 |
0 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
13.3 |
6.7 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Chemical/Drug
WY-14,643
|
C57BL/6JIco
inbred
|
0 |
6.7 |
|
|
|
|
Summary
|
Leukocyte lymphoma |
Leukocyte |
Chemical/Drug
WY-14,643
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Liver adenoma |
Liver |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 - observed |
|
|
|
|
Summary
|
Liver adenoma |
Liver |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
observed - 0.6 |
|
|
|
|
Summary
|
Liver adenoma |
Liver |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular adenoma |
Liver |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular adenoma |
Liver |
Chemical/Drug
WY-14,643
|
C57BL/6JIco
inbred
|
6.7 |
13.3 |
|
|
|
|
Summary
|
Liver hepatocellular adenoma |
Liver |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular adenoma |
Liver |
Chemical/Drug
WY-14,643
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 26.7 |
13.3 - 40 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
6.7 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
Chemical/Drug
WY-14,643
|
C57BL/6JIco
inbred
|
6.7 |
0 |
|
|
|
|
Summary
|
Liver hepatocellular carcinoma |
Liver |
Chemical/Drug
WY-14,643
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 6.7 |
0 - 6.7 |
|
|
|
|
Summary
|
Liver hyperplasia - oval cell |
Liver |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Liver hyperplasia - oval cell |
Liver |
Chemical/Drug
WY-14,643
|
C57BL/6JIco
inbred
|
46.7 |
40 |
|
|
|
|
Summary
|
Liver hyperplasia - oval cell |
Liver |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Liver hyperplasia - oval cell |
Liver |
Chemical/Drug
WY-14,643
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 6.7 |
13.3 - 26.7 |
|
|
|
|
Summary
|
Liver tumor |
Liver |
Chemical/Drug
p-cresidine
|
C57BL/6JIco
inbred
|
10 |
0 - 33.3 |
|
|
|
|
Summary
|
Liver tumor |
Liver |
Chemical/Drug
p-cresidine
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
6.7 - 20 |
0 - 53.3 |
|
|
|
|
Summary
|
Liver tumor |
Liver |
Chemical/Drug
p-cresidine
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
13.3 |
80 - 93.3 |
|
|
|
|
Summary
|
Liver tumor |
Liver |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6JIco
inbred
|
10 |
0 |
|
|
|
|
Summary
|
Liver tumor |
Liver |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
46.7 |
13.3 |
|
|
|
|
Summary
|
Liver tumor |
Liver |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
26.7 |
6.7 |
|
|
|
|
Summary
|
Lung adenoma |
Lung |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
2.5 - 6.7 |
|
|
|
|
Summary
|
Lung adenoma |
Lung |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 0.6 |
2.2 - 6.7 |
|
|
|
|
Summary
|
Lung adenoma |
Lung |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
2.3 - 6.7 |
0 - 0.7 |
|
|
|
|
Summary
|
Lung adenoma |
Lung |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Lung adenoma |
Lung |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
6.7 |
0 |
|
|
|
|
Summary
|
Lung adenoma |
Lung |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mammary gland adenocarcinoma |
Mammary gland |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mammary gland adenocarcinoma |
Mammary gland |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mammary gland adenocarcinoma |
Mammary gland |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
1.5 - 6.7 |
0 |
|
|
|
|
Summary
|
Mammary gland adenocarcinoma |
Mammary gland |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mammary gland adenocarcinoma |
Mammary gland |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mammary gland adenocarcinoma |
Mammary gland |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
CNS - Brain |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Abdominal cavity |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
CNS - Brain |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Abdominal cavity |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
CNS - Brain |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 - 6.7 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Abdominal cavity |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 - 6.7 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Skin |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Skin |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Abdominal cavity |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Skin |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Skin |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
CNS - Brain |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Abdominal cavity |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Skin |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
46.7 |
40 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Skin |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
33.3 |
20 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma |
Abdominal cavity |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Muscle - Smooth leiomyosarcoma |
Muscle - Smooth |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Muscle - Smooth leiomyosarcoma |
Muscle - Smooth |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Muscle - Smooth leiomyosarcoma |
Muscle - Smooth |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 |
0 |
|
|
|
|
Summary
|
Ovary - Germ cell teratoma |
CNS - Brain |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
|
|
|
|
|
Summary
|
Ovary - Germ cell teratoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
0 |
|
|
|
|
|
Summary
|
Ovary - Germ cell teratoma |
CNS - Brain |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Ovary - Germ cell teratoma |
CNS - Brain |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Ovary - Germ cell teratoma |
CNS - Brain |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Ovary - Germ cell teratoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Ovary - Granulosa cell tumor |
Ovary - Granulosa cell |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
|
|
|
|
|
Summary
|
Ovary - Granulosa cell tumor |
Ovary - Granulosa cell |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Ovary - Granulosa cell tumor |
Ovary - Granulosa cell |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 |
|
|
|
|
|
Summary
|
Ovary adenoma - tubulostromal |
Ovary |
None (spontaneous) |
C57BL/6JIco
inbred
|
0.8 |
|
|
|
|
|
Summary
|
Ovary adenoma - tubulostromal |
Ovary |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0.6 |
|
|
|
|
|
Summary
|
Ovary adenoma - tubulostromal |
Ovary |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Pituitary gland adenoma |
Pituitary gland |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Pituitary gland adenoma |
Pituitary gland |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
13.3 |
13.3 |
|
|
|
|
Summary
|
Pituitary gland adenoma |
Pituitary gland |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Pituitary gland adenoma |
Pituitary gland |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 13.3 |
0 - 33.3 |
|
|
|
|
Summary
|
Pituitary gland adenoma |
Pituitary gland |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Pituitary gland adenoma |
Pituitary gland |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
13.3 |
13.3 |
|
|
|
|
Summary
|
Placenta - Decidua deciduoma |
Placenta - Decidua |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
|
|
|
|
|
Summary
|
Placenta - Decidua deciduoma |
Placenta - Decidua |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0.6 |
|
|
|
|
|
Summary
|
Placenta - Decidua deciduoma |
Placenta - Decidua |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
|
|
|
|
|
Summary
|
Testis - Germ cell teratoma |
CNS - Brain |
None (spontaneous) |
C57BL/6JIco
inbred
|
|
0 |
|
|
|
|
Summary
|
Testis - Germ cell teratoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6JIco
inbred
|
|
0 |
|
|
|
|
Summary
|
Testis - Germ cell teratoma |
CNS - Brain |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
|
0 |
|
|
|
|
Summary
|
Testis - Germ cell teratoma |
CNS - Brain |
Hormone
estradiol (E2)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
|
0 |
|
|
|
|
Summary
|
Testis - Germ cell teratoma |
CNS - Brain |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
|
0 |
|
|
|
|
Summary
|
Testis - Germ cell teratoma |
CNS - Brain |
Hormone
estradiol (E2)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
|
6.7 |
|
|
|
|
Summary
|
Testis - Leydig cell (Interstitial cell) adenoma |
Testis - Leydig cell (Interstitial cell) |
None (spontaneous) |
C57BL/6JIco
inbred
|
|
0 |
|
|
|
|
Summary
|
Testis - Leydig cell (Interstitial cell) adenoma |
Testis - Leydig cell (Interstitial cell) |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
|
6.7 |
|
|
|
|
Summary
|
Testis - Leydig cell (Interstitial cell) adenoma |
Testis - Leydig cell (Interstitial cell) |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
|
0 |
|
|
|
|
Summary
|
Testis - Leydig cell (Interstitial cell) adenoma |
Testis - Leydig cell (Interstitial cell) |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
|
0 - 26.7 |
|
|
|
|
Summary
|
Testis - Leydig cell (Interstitial cell) adenoma |
Testis - Leydig cell (Interstitial cell) |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
|
0 |
|
|
|
|
Summary
|
Testis - Leydig cell (Interstitial cell) adenoma |
Testis - Leydig cell (Interstitial cell) |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
|
33.3 |
|
|
|
|
Summary
|
Thymus thymoma |
Thymus |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0 |
|
|
|
|
Summary
|
Thymus thymoma |
Thymus |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Thymus thymoma |
Thymus |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0.8 |
0 |
|
|
|
|
Summary
|
Thyroid gland - Follicular cell adenoma |
Thyroid gland - Follicular cell |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 |
0.8 |
|
|
|
|
Summary
|
Thyroid gland - Follicular cell adenoma |
Thyroid gland - Follicular cell |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Thyroid gland - Follicular cell adenoma |
Thyroid gland - Follicular cell |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 |
0 |
|
|
|
|
Summary
|
Urinary bladder preneoplastic lesion |
Urinary bladder |
Chemical/Drug
p-cresidine
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
|
observed |
|
|
|
|
Summary
|
Urinary bladder tumor |
Urinary bladder |
Chemical/Drug
p-cresidine
|
C57BL/6JIco
inbred
|
0 |
0 - 13.3 |
|
|
|
|
Summary
|
Urinary bladder tumor |
Urinary bladder |
Chemical/Drug
p-cresidine
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
6.7 |
0 - 13.3 |
|
|
|
|
Summary
|
Urinary bladder tumor |
Urinary bladder |
Chemical/Drug
p-cresidine
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
13.3 |
40 - 46.7 |
|
|
|
|
Summary
|
Urinary bladder tumor |
Urinary bladder |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6JIco
inbred
|
0 |
20 |
|
|
|
|
Summary
|
Urinary bladder tumor |
Urinary bladder |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
6.7 |
20 |
|
|
|
|
Summary
|
Urinary bladder tumor |
Urinary bladder |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
60 |
53.3 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
None (spontaneous) |
C57BL/6JIco
inbred
|
0 - 5.9 |
0 - 5.9 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
None (spontaneous) |
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 4.5 |
0 - 7.2 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
None (spontaneous) |
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
0 - 12.9 |
0 - 9.0 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
C57BL/6JIco
inbred
|
20 |
46.7 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
benzo[a]pyrene (BP) (BaP) (B[a]P)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
66.7 - 93.3 |
26.7 - 53.3 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
p-cresidine
|
C57BL/6JIco
inbred
|
10 |
0 - 46.7 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
p-cresidine
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
13.3 - 26.7 |
0 - 60 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
p-cresidine
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
26.7 |
80 - 93.3 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6JIco
inbred
|
10 |
20 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
46.7 |
26.7 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Chemical/Drug
2-acetamidofluorene (2-AAF)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
60 |
53.3 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Hormone
diethylstilbestrol (DES)
|
C57BL/6JIco
inbred
|
13.3 |
26.7 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Hormone
diethylstilbestrol (DES)
|
B6.129P2-Xpatm1Hvs
congenic
targeted mutation (knockout)
|
0 - 13.3 |
0 - 53.3 |
|
|
|
|
Summary
|
(Unspecified organ) tumor |
(Unspecified organ) |
Hormone
diethylstilbestrol (DES)
|
C57BL/6J-Trp53tm1Tyj/+ Xpatm1Hvs
targeted mutation (knockout)
|
46.7 |
86.7 |
|
|
|
|
Summary
|